Product Information
| Property | Description |
|---|---|
| Product Name | Anti-human CXCR2 Recombinant Monoclonal Antibody |
| Antibody ID | HM0076 |
| Target Protein | C-X-C chemokine receptor type 2 |
| Target Protein Short Name | CXCR2 |
| UniProt Accession | Human: P25025 |
| Molecular Weight | Human: 40.8 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Human |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | DFNMESDSFEDFWKGEDLSNYS |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C. |
| Research Use | For research use only. Not for diagnostic or therapeutic applications. |
Product Background
CXCR2 (C-X-C chemokine receptor type 2) is a G protein-coupled chemokine receptor involved in neutrophil recruitment, inflammatory signaling, angiogenesis, tumor progression, and immune cell migration. CXCR2 binds multiple ELR+ CXC chemokines and plays important roles in inflammatory diseases, cancer biology, infection, and immune responses.
CXCR2 is widely studied in immunology, inflammation biology, cancer research, chemokine signaling, GPCR biology, tumor microenvironment studies, and leukocyte trafficking.
Antibody Development
HM0076 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the CXCR2 epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot using recombinant MBP-epitope fusion protein
- Western blot detection of endogenous full-length CXCR2 protein
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc control protein.
Validation conditions:
- Well 1: Fc control protein
- Well 2: Epitope-Fc fusion protein
- Detection substrate: TMB
Note:
ELISA validation confirms binding to the epitope-Fc fusion antigen. Full-length CXCR2 protein binding in solution has not been tested by ELISA.
Western Blot Validation – Recombinant Fusion Protein
Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while minimal binding was observed against MBP control protein.
Validation conditions:
- Lane 1: MBP control protein
- Lane 2: MBP-epitope fusion protein
- Standard reducing Western blot
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous full-length CXCR2 protein under reducing conditions.
Validated samples:
- HeLa cells
- HepG2 cells
Detection condition:
- Standard reducing Western blot
- HRP-conjugated anti-mouse secondary antibody
Observed bands:
- Higher molecular weight bands may represent receptor glycosylation, oligomerization, receptor complexes, or post-translationally modified receptor species commonly observed for GPCR targets under reducing Western blot conditions.















